The correct identification of cases is an ally for the clinical treatment of hospitalizations due to acute respiratory tract infection
In early April, the Fiocruz InfoGripe Bulletin showed a significant growth, in 15 Brazilian states, of new hospitalizations of children due to Respiratory Syncytial Virus (RSV), the main causative agent of acute bronchiolitis and pneumonia.
The growth of demand for the test that detects the virus requires attention from laboratories, so that there is a correct identification of cases and their distinction from other viruses in circulation that cause symptoms that can be confused in clinical diagnosis.
The release of reliable reports promotes appropriate clinical conduct, guides public policies and seals the excellence of the laboratory.
In this sense, Controllab, the largest Quality Control Laboratory company in Latin America, provides quality programs for Respiratory Syncytial Virus in molecular routines and TLR/Point of Care. These are solutions that prevent errors in the analytical phase and costs in repetitions.
The prevention actions provided by quality tools are more efficient than correction actions, as they avoid wasting inputs, optimize human labor and make analyzes more productive and reliable.
Discover the solutions available for routine Respiratory Syncytial Virus and other respiratory diseases in this link.
